File downloaded on 2025-12-28

Source URL: https://medicines.health.europa.eu/veterinary/en/600000985594

Pyrocam 15 mg/ml oral suspension for pigs

Authorised

Meloxicam

Product identification

Medicine name:

Pyrocam 15 mg/ml oral suspension for pigs

Active substance:

Meloxicam

Target species:

Pig

Route of administration:

Oral use

Product details

Active substance and strength:

Meloxicam

15.00 milligram(s) / 1.00 millilitre(s)

Pharmaceutical form:

Oral suspension

Withdrawal period by route of administration: Oral use:

Pig

- Meat and offal. 5 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QM01AC06

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Hungary

Available in:

Hungary

Package description:

Cardboard box with HDPE bottle of 1000 ml closed with a two-part tamper evident closure consisting of an outer white cap (PP), an internal natural colour screw closure (HDPE) and a mounted plug (LDPE) + plastic measuring syringe

Cardboard box with HDPE bottle of 250 ml closed with a two-part tamper evident closure consisting of an outer white cap (PP), an internal natural colour screw closure (HDPE) and a mounted plug (LDPE) + plastic measuring syringe

Cardboard box with HDPE bottle of 125 ml closed with a two-part tamper evident closure consisting of an outer white cap (PP), an internal natural colour screw closure (HDPE) and a mounted plug (LDPE) + plastic measuring syringe

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Hybrid application – bioavailability studies cannot be used to demonstrate bioequivalence (Article 19(1)(b) of Regulation (EU) 2019/6)

Marketing authorisation holder:

HuVepharma

Marketing authorisation date:

17/11/2023

Manufacturing sites for batch release:

Biovet AD

Responsible authority:

Directorate Of Veterinary Medicinal Products

Authorisation number:

4409/1/23 NÉBIH ÁTI

Date of authorisation status change:

16/11/2023

Reference member state:

Belgium

Procedure number:

BE/V/0048/001

Concerned member states:

Austria Bulgaria Croatia Cyprus Czechia Denmark Estonia Finland France Germany Greece Hungary Ireland Italy Latvia Lithuania Luxembourg Malta Netherlands Norway Poland Portugal Romania Slovakia Slovenia Spain Sweden United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet